If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
LTB4 is synthesized in vivo from LTA4 by the enzyme LTA4 hydrolase. Its primary function is to recruit neutrophils to areas of tissue damage, though it also helps promote the production of inflammatory cytokines by various immune cells. Drugs that block the actions of LTB4 have shown some efficacy in slowing the progression of neutrophil-mediated diseases.
== External links == nobelprize.org Explaining the function of eukaryotic elongation factors Elongation+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Peptide+Elongation+Factor+G at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Peptide+Elongation+Factor+Tu at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 3.6.5.3
Once the relative volume occupied by PMN cells at the junctional epithelium reaches 60%, the junctional epithelium is unable to adhere to the root surface of the tooth and separates from it while the apical portion of the junctional epithelium migrates apically. This process, known as apical migration, results in the increase of the sulcular epithelium lining of this ‘false pocket’ (pseudopocket).
== Industrial applications == Imidazole itself has few direct applications. It is instead a precursor to a variety of agrichemicals, including enilconazole, climbazole, clotrimazole, prochloraz, and bifonazole.
=== Saccharides === The starting point for the discussion of carbohydrates is the saccharides. Monosaccharides are the simplest carbohydrates in that they cannot be hydrolyzed to smaller carbohydrates. Monosaccharides usually have the formula Cm (H2O)n. Disaccharides (e.g. sucrose) are common as are polysaccharides/oligosaccharides (e.g., starch, cellulose). Saccharides are polyhydroxy aldehydes, ketones as well as derived polymers having linkages of the acetal type. They may be classified according to their degree of polymerization. Many polyols are also classified as carbohydrates. In many carbohydrates the OH groups are appended to or replaced by N-acetyl (e.g., chitin), sulfate (e.g., glycosaminoglycans), carboxylic acid and deoxy modifications (e.g., fucose and sialic acid).
Sources: en.wikipedia.org
=== Filming === Principal photography for season 3 began in January 2025 and wrapped on November 15. The scenes set inside the strip club were shot first, in January. Filming was officially announced on February 10. Zendaya and Priscilla Delgado were spotted filming a scene from episode 2 on February 28. In March, Demie was shooting scenes from episode 5 with Akinnuoye-Agbaje. Domingo filmed some of his scenes involving Zendaya in March and returned to film the rest in July. Elordi and Dane started shooting in April. The wedding scenes were shot at the end of April. As a result of her busy schedule, Zendaya was forced to shoot all her scenes in a truncated timeline, saying: "It was a whirlwind. I did what I do in eight months in like four months. It was like trying to get eight episodes in at once. It just flew by me". She wrapped her scenes in June. Fike reportedly filmed a scene in September 2025, while Schafer was also filming. Elordi wrapped his scenes in October and Sweeney filmed her final scenes in November. The season was shot entirely on Kodak film stock. While the specials and season 2 were shot entirely in Super 35, season 3 was shot on 35 mm film with Arricam LT cameras and Panavision anamorphic lenses, and on 65 mm film with the Arriflex 765. Kodak created a film stock, Verita 200D 5206, in both formats specifically for the season. The aspect ratio also changed: season 1 was mostly in 16:9, season 2 mostly in widescreen, and season 3 is mostly in CinemaScope.
=== Other === Due to its naturally selective spectrum of activity, it is also employed as a selective agent in microbiological media to isolate gram-negative bacteria, yeast, and moulds. Nisin has also been used in food packaging applications and can serve as a preservative by controlled release onto the food surface from the polymer packaging. In combination with miconazole, it has been studied as a possible treatment for infections of Clostridioides difficile.
=== Diagnostic testing === Vitamin C content in plasma is used to determine vitamin status. For research purposes, concentrations can be assessed in leukocytes and tissues, which are normally maintained at an order of magnitude higher than in plasma via an energy-dependent transport system, depleted slower than plasma concentrations during dietary deficiency and restored faster during dietary repletion, but these analyses are difficult to measure, and hence not part of standard diagnostic testing.
=== Absolute glaucoma === Absolute glaucoma (H44.5) is the end stage of all types of glaucoma. The eye has no vision, absence of pupillary light reflex and pupillary response, and has a stony appearance. Severe pain is present in the eye. The treatment of absolute glaucoma is a destructive procedure, like cyclocryoapplication, cyclophotocoagulation, or injection of 99% alcohol.
== Uses == The sodium salt of pyroglutamic acid—known either as sodium pyroglutamate, sodium PCA, or sodium pidolate—is used for dry skin and hair products, as it is a humectant. It has low toxicity and is not a skin irritant, but its use in products is limited by a high price. L-pyroglutamic acid is sold online as a nootropic dietary supplement. Magnesium pidolate, the magnesium salt of pyroglutamic acid, is found in some mineral supplements. In a preclinical study, additional pharmacological properties of pyroglutamic acid were revealed such as anti-phosphodiesterase type 5, anti-angiotensin-converting enzyme, and anti-urease activities.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.